Explore Business Standard
Associate Sponsors
Co-sponsor
Aurobindo Pharma
Aurobindo Pharma is looking to ramp up the production of Penicillin-G to over 10,000 metric tonnes on an annual basis over the next 12 months, according to company CFO S Subramanian. The Hyderabad-based drug maker also expects its China-based manufacturing plant to break even in EBITDA in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year. "The ramp-up of the facility (Pen-G) is progressing in line with expectations and is well-positioned to deliver a meaningful uplift in profitability over time. Based on our current production level, we expect to produce more than 10,000 metric tonnes on an annualised basis over the next 12 months," Subramanian told analysts in a call. The company's Pen-G facility, located in a SEZ at Kakinada in Andhra Pradesh, is expected to touch production capacity of 15,000 metric tonnes per annum over a period of time. "It is important to note that the yield levels are steady and improving consistently over time," Subramanian said. Th
Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to Rs 910 crore for the December quarter, led by robust sales in Europe and the US. The Hyderabad-based drug major reported a net profit of Rs 846 crore for the October-December period of the last fiscal year. Total revenue from operations increased to Rs 8,646 crore during the quarter as compared with Rs 7,979 crore in the year-ago period, the drug firm said in a statement. "Q3 reflected steady execution across Aurobindo's core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the US and Europe," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability, he added. "As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation
Aurobindo Pharma on Thursday said the US health regulator has issued a Form 483 with five observations after inspecting Andhra Pradesh-based Unit-IV of its subsidiary APL Healthcare. The US Food and Drug Administration (USFDA) inspected the unit from December 8 to December 17, 2025, the Hyderabad-based drug firm said in a regulatory filing. "At the end of the inspection, a 'Form 483' was issued with 5 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines," it added. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, the drug firm said. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. Shares of Aurobindo Pharma were trading 0.83 per ..
Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.